Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs

@article{Pesu2005Jak3SC,
  title={Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs},
  author={Marko Pesu and Fabio Candotti and Matthew Husa and Sigrun R. Hofmann and Luigi Daniele Notarangelo and John J. O’Shea},
  journal={Immunological Reviews},
  year={2005},
  volume={203}
}
Summary:  The recent elucidation of the multiple molecular mechanisms underlying severe combined immunodeficiency (SCID) is an impressive example of the power of molecular medicine. Analysis of patients and the concomitant generation of animal models mimicking these disorders have quickly provided great insights into the pathophysiology of these potentially devastating illnesses. In this review, we summarize the discoveries that led to the understanding of the role of cytokine receptors and a… 
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
TLDR
Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection.
Human T cell immunodeficiency
TLDR
The first mutated signal transduction protein in T cells (ZAP-70); the first genetic defect leading to SCID and autoimmune phenomena (IL2Rα); and, recently, the critical importance of CD3δ in the development of T cells are described.
New JAK2 inhibitors for myeloproliferative neoplasms
TLDR
The discovery of the JAKV617F kinase established a common pathogenetic link to the most important types of Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs) and therefore any patient with MPN may benefit from therapy regardless of JAK2 mutational status.
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
TLDR
It appears that VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG), appears to offer potential for the treatment of a variety of autoimmune diseases.
Jakpot! New small molecules in autoimmune and inflammatory diseases
TLDR
New immunomodulators can inhibit signals from multiple cytokines intra‐cellularly and therefore could be useful when other therapies are ineffective, and may replace some traditional immunosuppressive agents and help patients not responding to previous therapies.
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
TLDR
Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.
Genetics of SCID
TLDR
This review is the updated, extended and largely modified translation of the article “Cossu F: Le basi genetiche delle SCID”, originally published in Italian language in the journal “Prospettive in Pediatria” 2009, 156:228-238.
Genetics of SCID
  • F. Cossu
  • Biology, Medicine
    Italian journal of pediatrics
  • 2010
TLDR
This review is the updated, extended and largely modified translation of the article "Cossu F: Le basi genetiche delle SCID", originally published in Italian language in the journal "Prospettive in Pediatria" 2009, 156: 228-238.
Selective inhibitors of the Janus kinase Jak3--Are they effective?
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 183 REFERENCES
Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency.
TLDR
The first naturally occurring mutations disrupting the function of the human Jak3 kinase domain are identified, and the model of the Jak3 protein permits us to study Jak3 phosphorylation at the structural level and may thus serve in the design of novel immune suppressive drugs.
In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction
TLDR
Data indicate that the biological defects of JAK3-deficient cells can be efficiently corrected in vitro by retroviral-mediated gene transfer, thus providing the basis for future investigation of gene therapy as treatment for Jak3- deficient SCID.
Molecular and biochemical characterization of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: implications for treatment
TLDR
The most common form of SCID (T−B+ SCID) is due to mutations of either the common gamma chain (γc) or of γc‐coupled JAK3 kinase, which is fatal unless treated by bone marrow transplantation (BMT).
Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.
TLDR
A major focus of this review will be the role of cytokines and their receptors in the pathogenesis of primary immunodeficiencies, and the identification of new genes associated with Immunodeficiency disorders.
Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency
TLDR
Molecular analysis at the JAK3 locus results in improved genetic counseling, allows early prenatal diagnosis, and prompts appropriate treatment in affected families, including clinical data on all of the 23 affected patients reported so far.
Severe combined immune deficiencies due to defects of the common γ chain-JAK3 signaling pathway
TLDR
The identification of two of the disease genes for T−B+SCID has made it possible to perform specific mutation analysis, thus allowing correct clinical diagnosis in sporadic cases of T+B+ SCID and, more importantly, opening the way to prenatal testing and direct assessment of carrier status.
Structural and functional basis for JAK3-deficient severe combined immunodeficiency.
TLDR
The characterization of the genetic defects and biochemical abnormalities in four new unrelated patients affected by JAK3-deficient SCID will help define the role of JAK2 in the ontogeny of a competent immune system and may lead to a better understanding of theJAK3 functional domains.
Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency.Defects of the gc‐JAK3 signaling pathway as a model
TLDR
An unexpected phenotypic heterogeneity of gamma(c) and JAK3 deficiency has emerged, indicating the need for appropriate and extensive investigations even in patients with atypical presentations.
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
TLDR
It is believed JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clinical settings.
Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation.
We found 10 individuals from 7 unrelated families among 170 severe combined immunodeficiency (SCID) patients who exhibited 9 different Janus kinase 3 (JAK3) mutations. These included 3 missense and 2
...
1
2
3
4
5
...